It's all about risk. Progress is good but it will need to remove some of the risk before we see a decent rise. I may have mentioned this a few times lately :)
All of the risks remain. Toxicology, manufacture, leading to paperwork and the trials probably in Q1 both here and China. None of this has been reduced as a result of todays announcements. But if and when each risk is removed we will see a price rise. Smallish steps at first (after any volatility settles down) but getting larger with the removal of each risk.
For me, one of the biggest non-science risks is the cost of Phase 1. SARs payment of £800k is for the pre-clinical work. BACIT have stated they expect to pay the same plus another £1.2m at some point. I can't see any reason to discount the possibility that SAR will need to find a similar amount for CHK1. I hope this isn't by another placing in the latter half of the year but there are other possibilities.
I think Tim is in an awkward (yet good) position whereby he knows the full potential of CHK1 and Aurora FLT3 and really does not want to deal on these before the Phase 1 trial results are known for less than he believes they are worth. If it works out it will see any potential deal command a very significant price. If it doesn't then with hindsight it will be the wrong strategy but that's life. But this 'licence at a later stage' approach costs money which has to come from somewhere.
If not a placing, then he has to deal on something else. Maybe some interest in TYK2/ JAK1 will come out of the conferences and he can licence that programme to cover the costs.
Couldnt agree more. Frustrating that this is taking so long to pull back to a decent level but we are heading in the rght direction, will take time, but we seem to have the right partners to do this with. There has been far to much ramping and building peoples expectaions up. Keep the faith and as always DYOR
1. Which 'competent team' do you wish the current management team to be replaced with? I though SAR only had 2 employees? I may be wrong since my info on that point is a bit dated. They may have increased their staffing by 50%. Therefore 3 employees. 2. Have you done your research? 3. Are you bitter and twisted because you jumped in a few years ago and lost money?
Looks like I am holding for longer but thats the risk of any share.
As TalkingSense sensibly says, the starting point for me is that there was no bad news.
CHK1- nothing really new from the patent update end-Jan and previous news. The final paragraph, where it states that "the directors note with interest recent reports in scientifdic literature", could have been written much better in my view, simply by adding what this could mean to Sareum's future plans rather than just leaving it hanging. Seems a missed opportunity in my humble opinion.
Aurora+FLT3 - nothing more to see here. Certainly not the fast track good news that a certain poster or two was expecting to be announced. But nothing at all that disappoints.
TYK2+JAK1 - thought there are some small positives here if digging deep enough. The promise of study results in scientific literature and conference presentations provides potential catalysts throughout the year. There are so many conferences that it is impossible to narrow these down but we may see Tim at the big dermatology/psoriasis conferences in Miami/San Diego before too long!
So overall, a bit of a damp squib if truth be known but nothing that makes me too disappointed. Slowly slowly catch the monkey and all that. This time next decade Rodney......
Think there may be some disappointment from those who were "street wise enough to know that something was going on behind the scenes" by the fact that there is very limited fundamental improvement to drive the SP higher based on this update, whilst I think the majority of holders will continue to hold/accumulate when the more short-term focused investors bail. Ultimately, they may be right to bail - such is the nature of very junior biotech investing - but as stated, I'm not too surprised/disappointed by today's update.
So Sar in collaboration with CRUK one of the world's leading cancer research institutions, with China the world's biggest potential market, US patent for Skil platform - for a drug discovery company yeah they do sound a total mess-up lol.......me thinks some people didn't do too much research when they invested here.
Of course great risk as highlighted by many a positive poster on here, but any "discovery" company needs progress and thats what we got today no more no less......anyway off to the slopes now so GLA and DYOR
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.